Literature DB >> 27010867

Early Stage of Hyperintense Acute Reperfusion Marker on Contrast-Enhanced FLAIR Images in Patients With Acute Stroke.

Kyung Mi Lee1,2, Jae Hyoung Kim1, Eunhee Kim1, Byung Se Choi1, Yun Jung Bae1, Hee-Joon Bae3.   

Abstract

OBJECTIVE: Hyperintense acute reperfusion marker (HARM) is defined as delayed CSF enhancement on FLAIR images in patients with acute stroke and was observed in follow-up FLAIR images after initial MRI with contrast material administration. We hypothesized that different imaging findings of HARM could be present depending on the timing of FLAIR imaging after contrast material administration. SUBJECTS AND METHODS: Of 218 consecutive patients with acute stroke or transient ischemic attack over 3 months, 12 with linear contrast enhancement on the cortical surface in initial FLAIR images underwent serial FLAIR imaging. Initial FLAIR images were obtained 5 minutes after contrast material administration, and follow-up unenhanced FLAIR images were obtained 2.5-29 hours (mean, 13.2 hours) after initial FLAIR imaging. The enhancement patterns between initial and follow-up FLAIR images were compared.
RESULTS: In all 12 patients, initial contrast-enhanced FLAIR images showed focal or multifocal linear contrast enhancement along the cortical surface near acute infarctions. On follow-up unenhanced FLAIR images, initial cortical enhancement spread diffusely and filled the subarachnoid space.
CONCLUSION: HARM in acute stroke can be detected earlier than previously reported on initial contrast-enhanced FLAIR images. Different imaging findings of HARM depend on the timing of FLAIR imaging after contrast material administration.

Entities:  

Keywords:  acute ischemic stroke; blood-brain barrier; contrast-enhanced FLAIR image; hyperintense acute reperfusion marker

Mesh:

Substances:

Year:  2016        PMID: 27010867     DOI: 10.2214/AJR.15.14857

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  6 in total

1.  Hyperintense acute reperfusion marker associated with hemorrhagic transformation in the WAKE-UP trial.

Authors:  Anke Wouters; Lauranne Scheldeman; Patrick Dupont; Bastian Cheng; Martin Ebinger; Märit Jensen; Matthias Endres; Christian Gerloff; Keith W Muir; Norbert Nighoghossian; Salvador Pedraza; Claus Z Simonsen; Florent Boutitie; Vincent Thijs; Götz Thomalla; Jochen Fiebach; Robin Lemmens
Journal:  Eur Stroke J       Date:  2021-06-12

Review 2.  Neuroinflammation, Stroke, Blood-Brain Barrier Dysfunction, and Imaging Modalities.

Authors:  Eduardo Candelario-Jalil; Rick M Dijkhuizen; Tim Magnus
Journal:  Stroke       Date:  2022-04-07       Impact factor: 10.170

3.  Usefulness of hyperintense acute reperfusion marker sign in patients with transient neurologic symptom.

Authors:  Jihoon Kang; Hyuksool Kwon; Cheol Kyu Jung; Hee-Joon Bae; Moon-Ku Han; Beom Joon Kim; You Hwan Jo
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

4.  Contrast leakage distant from the hematoma in patients with spontaneous ICH: A 7 T MRI study.

Authors:  Wilmar Mt Jolink; Arjen Lindenholz; Ellis S van Etten; Koen M van Nieuwenhuizen; Floris Hbm Schreuder; Hugo J Kuijf; Matthias Jp van Osch; Jeroen Hendrikse; Gabriel Je Rinkel; Marieke Jh Wermer; Catharina Jm Klijn
Journal:  J Cereb Blood Flow Metab       Date:  2019-05-29       Impact factor: 6.200

5.  Role of Hyperintense Acute Reperfusion Marker for Classifying the Stroke Etiology.

Authors:  Hee Young Choi; Kyung Mi Lee; Hyug-Gi Kim; Eui Jong Kim; Woo Suk Choi; Bum Joon Kim; Sung Hyuk Heo; Dae-Il Chang
Journal:  Front Neurol       Date:  2017-11-29       Impact factor: 4.003

Review 6.  CSF enhancement on post-contrast fluid-attenuated inversion recovery images; a systematic review.

Authors:  Whitney M Freeze; Merel van der Thiel; Jeroen de Bresser; Catharina J M Klijn; Ellis S van Etten; Jacobus F A Jansen; Louise van der Weerd; Heidi I L Jacobs; Walter H Backes; Susanne J van Veluw
Journal:  Neuroimage Clin       Date:  2020-10-02       Impact factor: 4.881

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.